Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anti‑epileptic presented as an intravenous solution for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and is administered under medical supervision in hospital settings.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinical centres worldwide, ensuring quality, regulatory compliance, and reliable delivery across global markets with dedicated customer support and traceability throughout the supply chain.

Lacosamide is an anti‑epileptic that acts on neuronal sodium channels to control seizure activity. It is used in the following clinical situations: - Partial‑onset seizures: reduces seizure frequency as an add‑on therapy in epilepsy patients. - Focal epilepsy: improves overall seizure control when combined with other antiepileptic drugs. - Refractory epilepsy: provides an additional mechanism of action for patients not adequately controlled by existing therapies.

Lacosamide may cause a range of adverse reactions. Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial discomfort. - Nausea: occasional upset stomach. - Fatigue: feeling of tiredness or reduced energy. - Blurred vision: temporary visual disturbances. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or atrial fibrillation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, itching, or anaphylaxis. - Suicidal ideation: emergence of depressive thoughts. - Respiratory depression: reduced breathing effort in vulnerable patients. - Hepatic dysfunction: elevated liver enzymes indicating liver stress.

When prescribing Lacosamide, consider the following precautions: - Renal impairment: monitor renal function and adjust therapy as needed. - Cardiac conduction disorders: obtain baseline ECG and observe for PR‑interval changes. - Pregnancy: safety not established; weigh potential benefits against risks. - Concomitant CNS depressants: may increase sedation or respiratory depression. - Hepatic impairment: use with caution and monitor liver enzymes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medications. Major Interactions (Avoid):\n- Class I antiarrhythmics (e.g., quinidine): may exacerbate PR‑interval prolongation. - Carbamazepine: may reduce lacosamide plasma concentrations. - Other sodium‑channel blockers: risk of additive central nervous system effects.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Anticoagulants (e.g., warfarin): potential increased bleeding risk. - Hormonal contraceptives: may decrease contraceptive efficacy.